Currently, ceftobiprole has completed Phase III trials for complicated skin and skin structure infections (cSSSIs), and has been selected for the treatment of community-associated and hospital-acquired pneumonia. The present study sought to evaluate the in vitro activity of ceftobiprole and cefepime against enterococci and E. coli isolated from humans and animals, as well as human clinical isolates of MRSA and methicillin-susceptible S. aureus (MSSA).
Sir, Ceftobiprole (previously known as BAL9141), the active component of the prodrug ceftobiprole medocaril, is a new broad-spectrum cephalosporin that displays a potent antimicrobial activity against most clinically important bacteria. Previous surveys have shown that ceftobiprole is active in vitro against Gram-positive strains, including methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant coagulase-negative staphylococci (MRCoNS), penicillin-resistant Streptococcus pneumoniae (PRSP) and vancomycin-resistant enterococci (VRE), and Gramnegative bacteria, including Escherichia coli and Pseudomonas aeruginosa. 1 -3 Ceftobiprole has been shown to be effective in several animal models, including infections caused by MRSA. 1 Currently, ceftobiprole has completed Phase III trials for complicated skin and skin structure infections (cSSSIs), and has been selected for the treatment of community-associated and hospital-acquired pneumonia. 4 The present study sought to evaluate the in vitro activity of ceftobiprole and cefepime against enterococci and E. coli isolated from humans and animals, as well as human clinical isolates of MRSA and methicillin-susceptible S. aureus (MSSA).
A total of 1044 isolates were tested, comprising 522 enterococci and 416 E. coli [62 of which produced extended-spectrum b-lactamases (ESBLs)] recovered from faecal samples of humans and animals, together with 74 MRSA and 32 MSSA. The sources of the isolates are shown in Table 1 . The enterococci were identified to species level using specific primers as described previously. 5 Ceftobiprole was obtained from Johnson & Johnson Pharmaceutical Research and Development (Raritan, NJ, USA) and cefepime was obtained from Sigma-Aldrich (Madrid, Spain). Ceftobiprole and cefepime dilutions were prepared and dissolved as recommended by the manufacturer. The MICs of ceftobiprole and cefepime were determined using the CLSI microbroth dilution method. 6 The reference strains tested included S. aureus ATCC 25923, Enterococcus faecalis ATCC 29212 and E. coli ATCC 25922.
The activity of ceftobiprole and cefepime against the isolates of various origins is shown in Table 1 . While cefepime showed little activity against E. faecalis (MIC 90 .128 mg/L) all E. faecalis isolates tested were inhibited by 4 mg/L ceftobiprole (MIC 90 1 mg/L), irrespective of the source of isolation. In contrast, the MICs of both cephalosporins for the E. faecium isolates were high (ceftobiprole MIC 90 128 mg/L and cefepime MIC 90 !128 mg/L). The SENTRY antimicrobial surveillance programme study, recently performed in America and Europe, has reported similar results to those obtained with ceftobiprole against enterococci. 2 The activities of ceftobiprole and cefepime were similar against isolates of E. coli that did not produce ESBLs, although the MIC 50 and MIC 90 values (0.25-1 mg/L and 1-2 mg/L, respectively) were higher than those reported in other studies. 2, 3 In contrast, the activity of ceftobiprole against ESBL-producing E. coli was significantly reduced (MIC 50 and MIC 90 values of 128 mg/L), while cefepime showed lower MIC values (MIC 50 8 mg/L and MIC 90 64 mg/L). These results showed that ceftobiprole activity against E. coli depended largely on the b-lactam resistance phenotypes of the tested isolates. As shown in our study, ceftobiprole was found to be largely inactive against ESBL-producing Gram-negative strains. 
Research letters
In summary, the current study shows that ceftobiprole has good in vitro activity against E. faecalis and E. coli isolates from different human and animal origins and proved to be a potent antimicrobial agent against MRSA and MSSA irrespective of their susceptibilities to cefepime.
